For example, SLC1A5 (also known as ASCT2), a neutral amino acids transporter, was shown to be a potential therapeutic target for melanoma, as the transporter activity could be reduced by a specific inhibitor and thereby reduce the amount of amino acid uptake and subsequently cell proliferation and cell cycle progression [9]. The gene discussed is SLC1A5; the disease is melanoma.